Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.80 Average Target Price from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given a consensus recommendation of “Moderate Buy” by the five analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $43.80.

COLL has been the subject of a number of research reports. Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 3.98% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Large investors have recently bought and sold shares of the business. Rhumbline Advisers boosted its stake in Collegium Pharmaceutical by 2.8% in the second quarter. Rhumbline Advisers now owns 107,364 shares of the specialty pharmaceutical company’s stock worth $3,457,000 after purchasing an additional 2,966 shares in the last quarter. TD Asset Management Inc grew its holdings in Collegium Pharmaceutical by 172.7% during the 2nd quarter. TD Asset Management Inc now owns 15,000 shares of the specialty pharmaceutical company’s stock worth $483,000 after acquiring an additional 9,500 shares during the last quarter. Choreo LLC acquired a new stake in Collegium Pharmaceutical in the 2nd quarter valued at about $396,000. American Century Companies Inc. lifted its position in shares of Collegium Pharmaceutical by 8.8% during the second quarter. American Century Companies Inc. now owns 99,808 shares of the specialty pharmaceutical company’s stock worth $3,214,000 after purchasing an additional 8,097 shares in the last quarter. Finally, BOKF NA bought a new stake in shares of Collegium Pharmaceutical during the second quarter valued at approximately $490,000.

Collegium Pharmaceutical Stock Down 0.3 %

NASDAQ COLL opened at $33.35 on Monday. Collegium Pharmaceutical has a twelve month low of $28.39 and a twelve month high of $42.29. The stock has a market cap of $1.08 billion, a PE ratio of 14.38 and a beta of 0.82. The firm has a 50-day simple moving average of $30.54 and a 200 day simple moving average of $34.09. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.